What's Happening?
Abbisko Therapeutics has announced positive preliminary efficacy results from its Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, for children with achondroplasia (ACH). In the initial
and lowest dose cohort (0.064mg/kg QD), children aged 6 years and older with ACH who received lavengratinib for 27 weeks showed a mean increase of +2.4 cm/year in annualized height velocity (AHV) from baseline, achieving a 100% responder rate. The drug was well-tolerated, with no observed FGFR1 or FGFR2-associated adverse events. The ABSK061-202 study is a Phase II, multicenter, open-label, dose-escalation study evaluating the safety and efficacy of lavengratinib in children aged 3 to 12 years with ACH, with a planned treatment duration of 78 weeks. Preliminary safety evaluations for the first three dose cohorts have been successfully completed without identifying any safety concerns.
Why It's Important?
This development is significant for the achondroplasia community, a rare genetic disorder that is the most common cause of dwarfism. The positive preliminary results suggest a potential new therapeutic option that could improve growth rates in affected children. Lavengratinib has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA), highlighting the urgent need for effective treatments for this condition. The drug's favorable safety profile, particularly the absence of FGFR1 or FGFR2-associated adverse events, is crucial as previous pan-FGFR inhibitors have faced limitations due to side effects. A successful treatment could significantly enhance the quality of life for children with achondroplasia by promoting growth and potentially reducing associated health complications.
What's Next?
The ABSK061-202 study is ongoing, with participants in higher dose cohorts currently receiving treatment. Six-month efficacy and safety results for the study are anticipated by the end of 2026. These upcoming results will provide further evidence to support the evaluation of lavengratinib's clinical potential. If the positive trends continue, Abbisko Therapeutics will likely proceed with further clinical development, potentially leading to regulatory submissions for approval. The company's unique oral mini-tablet formulation, designed for easy administration in children, could also facilitate broader adoption if the drug is approved. Continued monitoring of long-term efficacy and safety will be critical as the study progresses.
Beyond the Headlines
The development of lavengratinib represents a broader trend in pharmaceutical research focusing on targeted therapies for rare diseases. The drug's design as a selective FGFR2/3 inhibitor aims to overcome the limitations of earlier pan-FGFR inhibitors by minimizing off-target effects, particularly those related to FGFR1. This approach could set a precedent for developing more precise and safer treatments for other conditions involving FGFR pathway dysregulation. The FDA's Rare Pediatric Disease Designation and Orphan Drug Designation not only accelerate the review process but also provide incentives for companies to invest in treatments for conditions affecting small patient populations, underscoring a commitment to addressing unmet medical needs in pediatric health.
